Mainz Biomed B.v. Stock
Price
Target price
€6.64
€6.64
-1.480%
-0.1
-1.480%
-
05.12.24 / Stuttgart Stock Exchange
WKN: A3C6XX / Name: Mainz Biomed B.v. / Stock / ? /
We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Mainz Biomed B.v. is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Mainz Biomed B.v.
sharewise wants to provide you with the best news and tools for Mainz Biomed B.v., so we directly link to the best financial data sources.
Financials
News
EQS-News: Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
EQS-News: Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
EQS-News: Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
EQS-News: Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
EQS-News: Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
EQS-News: Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
EQS-News: Mainz Biomed Enters into Technology Partnership with EDX Medical Group
EQS-News: Mainz Biomed Enters into Technology Partnership with EDX Medical Group
EQS-News: Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
EQS-News: Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
EQS-News: Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
EQS-News: Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
EQS-News: Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
EQS-News: Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
EQS-News: Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
EQS-News: Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
EQS-News: Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
EQS-News: Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
EQS-News: Mainz Biomed Expands into Switzerland with labor team w
EQS-News: Mainz Biomed Expands into Switzerland with labor team w
EQS-News: Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
EQS-News: Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
EQS-News: Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
EQS-News: Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
EQS-News: Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
EQS-News: Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population